Comparison of the Feasibility and Safety of First- versus Second-Generation AMPLATZER™ Occluders for Left Atrial Appendage Closure

Introduction. Left atrial appendage closure (LAAC) is considered an alternative to oral anticoagulation therapy in patients with atrial fibrillation (AF). The aim of this study was to compare the safety and efficacy of the first- and second-generation AMPLATZER Devices for LAAC, AMPLATZER Cardiac Pl...

Full description

Bibliographic Details
Main Authors: Baravan Al-Kassou, Heyder Omran
Format: Article
Language:English
Published: Hindawi Limited 2017-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2017/1519362
id doaj-464c1c6804214f39983d95e6a25ead59
record_format Article
spelling doaj-464c1c6804214f39983d95e6a25ead592020-11-25T00:08:38ZengHindawi LimitedBioMed Research International2314-61332314-61412017-01-01201710.1155/2017/15193621519362Comparison of the Feasibility and Safety of First- versus Second-Generation AMPLATZER™ Occluders for Left Atrial Appendage ClosureBaravan Al-Kassou0Heyder Omran1Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, GermanyGFO Kliniken Bonn, Robert-Koch-Str. 1, 53115 Bonn, GermanyIntroduction. Left atrial appendage closure (LAAC) is considered an alternative to oral anticoagulation therapy in patients with atrial fibrillation (AF). The aim of this study was to compare the safety and efficacy of the first- and second-generation AMPLATZER Devices for LAAC, AMPLATZER Cardiac Plug (ACP) versus AMPLATZER Amulet™. Methods. Procedural data, such as fluoroscopy time, radiation dose, and contrast-dye, as well as VARC criteria and major adverse events (MAEs) were assessed for both devices. The rate of peridevice leaks was analyzed at echocardiographic follow-up. Results. A total of 196 patients with AF underwent LAAC with the ACP (n=99) or Amulet device (n=97). The use of Amulet was associated with significantly lower fluoroscopy time (14.8 ± 7.4 min versus 10.6 ± 4.1 min; p<0.001), lower radiation dose (4833 ± 3360 cGy⁎cm2 versus 3206 ± 2169 cGy⁎cm2; p<0.001), and reduced amount of contrast-dye (150.2 ± 83.9 ml versus 128.8 ± 46.0 ml; p=0.03). Furthermore, LAAC with Amulet devices resulted in lower device-resizing rates (3 versus 16 cases; p=0.001). Peridevice leaks were less frequent in the Amulet group (12 versus 4; p=0.03). MAE occurred in 6 ACP and 4 Amulet patients (p=0.58). Conclusions. The Amulet device is associated with shorter fluoroscopy times and radiation dosages, reduced use of contrast-dye, lower recapture rates, and less peridevice leaks as compared to the ACP.http://dx.doi.org/10.1155/2017/1519362
collection DOAJ
language English
format Article
sources DOAJ
author Baravan Al-Kassou
Heyder Omran
spellingShingle Baravan Al-Kassou
Heyder Omran
Comparison of the Feasibility and Safety of First- versus Second-Generation AMPLATZER™ Occluders for Left Atrial Appendage Closure
BioMed Research International
author_facet Baravan Al-Kassou
Heyder Omran
author_sort Baravan Al-Kassou
title Comparison of the Feasibility and Safety of First- versus Second-Generation AMPLATZER™ Occluders for Left Atrial Appendage Closure
title_short Comparison of the Feasibility and Safety of First- versus Second-Generation AMPLATZER™ Occluders for Left Atrial Appendage Closure
title_full Comparison of the Feasibility and Safety of First- versus Second-Generation AMPLATZER™ Occluders for Left Atrial Appendage Closure
title_fullStr Comparison of the Feasibility and Safety of First- versus Second-Generation AMPLATZER™ Occluders for Left Atrial Appendage Closure
title_full_unstemmed Comparison of the Feasibility and Safety of First- versus Second-Generation AMPLATZER™ Occluders for Left Atrial Appendage Closure
title_sort comparison of the feasibility and safety of first- versus second-generation amplatzer™ occluders for left atrial appendage closure
publisher Hindawi Limited
series BioMed Research International
issn 2314-6133
2314-6141
publishDate 2017-01-01
description Introduction. Left atrial appendage closure (LAAC) is considered an alternative to oral anticoagulation therapy in patients with atrial fibrillation (AF). The aim of this study was to compare the safety and efficacy of the first- and second-generation AMPLATZER Devices for LAAC, AMPLATZER Cardiac Plug (ACP) versus AMPLATZER Amulet™. Methods. Procedural data, such as fluoroscopy time, radiation dose, and contrast-dye, as well as VARC criteria and major adverse events (MAEs) were assessed for both devices. The rate of peridevice leaks was analyzed at echocardiographic follow-up. Results. A total of 196 patients with AF underwent LAAC with the ACP (n=99) or Amulet device (n=97). The use of Amulet was associated with significantly lower fluoroscopy time (14.8 ± 7.4 min versus 10.6 ± 4.1 min; p<0.001), lower radiation dose (4833 ± 3360 cGy⁎cm2 versus 3206 ± 2169 cGy⁎cm2; p<0.001), and reduced amount of contrast-dye (150.2 ± 83.9 ml versus 128.8 ± 46.0 ml; p=0.03). Furthermore, LAAC with Amulet devices resulted in lower device-resizing rates (3 versus 16 cases; p=0.001). Peridevice leaks were less frequent in the Amulet group (12 versus 4; p=0.03). MAE occurred in 6 ACP and 4 Amulet patients (p=0.58). Conclusions. The Amulet device is associated with shorter fluoroscopy times and radiation dosages, reduced use of contrast-dye, lower recapture rates, and less peridevice leaks as compared to the ACP.
url http://dx.doi.org/10.1155/2017/1519362
work_keys_str_mv AT baravanalkassou comparisonofthefeasibilityandsafetyoffirstversussecondgenerationamplatzeroccludersforleftatrialappendageclosure
AT heyderomran comparisonofthefeasibilityandsafetyoffirstversussecondgenerationamplatzeroccludersforleftatrialappendageclosure
_version_ 1725415282679218176